Publications:
Other Publications
Oct
2024
Taurolidine-containing solution for reducing cardiac implantable electronic device infection-early report from the European TauroPace™ registry.
Vonthein R, Baldauf B, Borov S, Lau EW, Giaccardi M, Assadian O, Haddad C, Chévalier P, Bode K, Foley P, Thomas H, Campbell NG, Fichtner S, Donazzan L, Pescoller F, Oberhollenzer R, Cemin R, Bonnemeier H.
J Cardiothorac Surg. 2024 Oct 4;19(1):592. doi: 10.1186/s13019-024-03059-1.
PMID: 39367427 Free PMC article.
Oct
2024
High lead-related complication rate with MicroPort Vega active fixation pacing leads.
Özkartal T, Bergonti M, Caputo ML, Costantino J, Klersy C, Conte G.
Europace. 2024 Oct 3;26(10):euae242. doi: 10.1093/europace/euae242. PMID: 39288313 Free PMC article. No abstract available.
Oct
2024
Cardiac resynchronization therapy guided by interventricular conduction delay: How to choose between biventricular pacing or conduction system pacing.
Marallo C, Landra F, Taddeucci S, Collantoni M, Martini L, Lunghetti S, Pagliaro A, Menci D, Baiocchi C, Fineschi M, Santoro A.
J Cardiovasc Electrophysiol. 2024 Dec;35(12):2345-2353. doi: 10.1111/jce.16433. Epub 2024 Oct 3. PMID: 39363418 Clinical Trial.
Sep
2024
Risk factors associated with clinically relevant pericardial effusion after primary cardiac implantable electronic device implantation.
Zhou Y, Haxha S, Halili A, Philbert BT, Nielsen OW, Sajadieh A, Koeber L, Gislason GH, Torp-Pedersen C, Bang CN.
J Cardiovasc Electrophysiol. 2024 Sep 30. doi: 10.1111/jce.16442. Online ahead of print. PMID: 39350327
Sep
2024
Comparing complication rates between Abbott Tendril 2088 and competitive manufacturer leads: Novel real-world data approach
Ahmed A, Wilkoff BL, Kim JA, Nabutovsky Y, Kim G, Desmond M, Ganz L, Curtis AB.
J Cardiovasc Electrophysiol. 2024 Sep 29. doi: 10.1111/jce.16437. Online ahead of print. PMID: 39344010